Pinostilbene inhibits lung epithelial-mesenchymal transition and delays pulmonary fibrosis by modulating the PI3K/Akt pathway
Frontiers in Pharmacology · 05.09.2025 · 16
DOI: 10.3389/fphar.2025.1614546 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 05.09.2025. Verfasst von Xin Yu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Innovative Institute of Chinese Medicine and Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Epithelial-mesenchymal transition (EMT) in the lung is a key process in which pulmonary epithelial cells lose epithelial characteristics and acquire mesenchymal properties, contributing to conditions such as pulmonary fibrosis. This study investigates the potential of pinostilbene (PIN), a natural stilbene compound with known anti-cancer, antioxidant and anti-inflammatory properties, to inhibit pulmonary EMT. Cellular experiments using A549 and Beas2B cells showed that PIN significantly reduced TGF-β1-induced mesenchymal marker expression while increasing epithelial marker expression. Functional assays confirmed the ability of PIN to inhibit cell migration and adhesion. In vivo , PIN alone or in combination with pirfenidone effectively alleviated lung damage in a murine lung fibrosis model, as demonstrated by histological analysis. Mechanistic studies identified the PI3K/Akt pathway as a target of PIN, with Western blot analysis showing decreased phosphorylation levels of PI3K and Akt. These findings suggest that PIN inhibits pulmonary EMT and delays the progression of pulmonary fibrosis by modulating the PI3K/Akt pathway, providing a promising therapeutic avenue for lung diseases associated with EMT.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Innovative Institute of Chinese Medicine and Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, China.
- Department of Orthopedics, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.
- Experimental Center, Shandong University of Traditional Chinese Medicine, Jinan, China.
- Department of Radiation Oncology Physics and Technology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
- Key Laboratory of Traditional Chinese Medicine Classical Theory, Ministry of Education, Shandong University of Traditional Chinese Medicine, Jinan, China.
Förderung
- Natural Science Foundation of Shandong Province
Zitieren
APA
Yu, X., Xiao, L., Zhu, J., Sun, T., Gong, K., Kou, X., Zhou, Y., Xu, M., Lu, K., Sun, H., Guan, H., & Liu, C. (2025). Pinostilbene inhibits lung epithelial-mesenchymal transition and delays pulmonary fibrosis by modulating the PI3K/Akt pathway. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1614546
Vancouver
Yu X, Xiao L, Zhu J, Sun T, Gong K, Kou X, et al. Pinostilbene inhibits lung epithelial-mesenchymal transition and delays pulmonary fibrosis by modulating the PI3K/Akt pathway. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1614546
BibTeX
@article{Yu2025,
author = {Yu, Xin and Xiao, Li and Zhu, Jiang and Sun, Tianying and Gong, Kai and Kou, Xuefang and Zhou, Yuhe and Xu, Mengzhen and Lu, Kaihui and Sun, Hua and Guan, Haixing and Liu, Chuanguo},
title = {Pinostilbene inhibits lung epithelial-mesenchymal transition and delays pulmonary fibrosis by modulating the PI3K/Akt pathway},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1614546}
}
EUVIMED